Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$1.75 - $3.44 $488,775 - $960,792
279,300 Added 45.98%
886,800 $2.93 Billion
Q4 2023

Feb 14, 2024

BUY
$1.74 - $2.31 $1.06 Million - $1.4 Million
607,500 New
607,500 $1.28 Billion

Others Institutions Holding GERN

About GERON CORP


  • Ticker GERN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 377,819,008
  • Market Cap $1.63B
  • Description
  • Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hemat...
More about GERN
Track This Portfolio

Track Exome Asset Management LLC Portfolio

Follow Exome Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Exome Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Exome Asset Management LLC with notifications on news.